Brainomix

Brainomix’s AI-powered imaging platforms are clinically validated and commercially deployed in over twenty countries. The company’s flagship product, Brainomix 360 Stroke, has demonstrated a significant impact on treatment rates—associated with a reported additional 50% increase in the number of patients receiving mechanical thrombectomy for stroke. Its e-Lung technology for lung fibrosis has received FDA clearance and supports early diagnosis and prediction of disease progression. The company’s solutions have been adopted by more than three hundred hospitals worldwide, benefiting over one and a half million patients. Clinical partnerships with major pharma companies are ongoing to further validate real-world impact.